Back to Search
Start Over
Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer.
- Source :
- Cancers; Dec2023, Vol. 15 Issue 23, p5505, 22p
- Publication Year :
- 2023
-
Abstract
- Simple Summary: Despite the use of novel agents in the first-line therapeutic setting, such as PD-1/PDL1 axis blockers for non-oncogene addicted non-small-cell lung cancer, most patients with advanced disease experience progression will succumb to the illness within a short period of time. Currently, the standard second-line treatment consists primarily of systemic cytotoxic therapies, which typically yield poor outcomes. Recently, several novel therapeutic strategies have emerged that may improve patient outcomes. This article reviews current state-of-the-art treatments in this scenario and highlights potential future options. Immune checkpoint inhibitors (ICIs) have revolutionized the management of non-oncogene addicted non-small-cell lung cancer (NSCLC). Blocking the anti-PD-1 axis represents the current standard of care in the first-line setting, with drugs administered either as monotherapy or in combination with chemotherapy. Despite notable successes achieved with ICIs, most of their long-term benefits are restricted to approximately 20% of patients. Consequently, the post-failure treatment landscape after failure to first-line treatment remains a complex challenge. Currently, docetaxel remains the preferred option, although its benefits remain modest as most patients do not respond or progress promptly. In recent times, novel agents and treatment combinations have emerged, offering fresh opportunities to improve patient outcomes. ICIs combined either with antiangiogenic or other novel immunotherapeutic compounds have shown promising preliminary activity. However, more mature data concerning specific combinations do not support their benefit over standard of care. In addition, antibody–drug conjugates seem to be the most promising alternative among all available compounds according to already-published phase I/II data that will be confirmed in soon-to-be-published phase III trial data. In this report, we provide a comprehensive overview of the current second-line treatment options and discuss future therapeutic perspectives. [ABSTRACT FROM AUTHOR]
- Subjects :
- THERAPEUTIC use of monoclonal antibodies
THERAPEUTIC use of antineoplastic agents
LUNG cancer
DISEASE progression
PROGRAMMED cell death 1 receptors
IMMUNE checkpoint inhibitors
NEOVASCULARIZATION inhibitors
IMMUNOGLOBULINS
TREATMENT failure
TREATMENT effectiveness
DOCETAXEL
QUALITY assurance
COMBINED modality therapy
ALTERNATIVE medicine
PROGRESSION-free survival
IMMUNOTHERAPY
OVERALL survival
ALGORITHMS
Subjects
Details
- Language :
- English
- ISSN :
- 20726694
- Volume :
- 15
- Issue :
- 23
- Database :
- Complementary Index
- Journal :
- Cancers
- Publication Type :
- Academic Journal
- Accession number :
- 174115254
- Full Text :
- https://doi.org/10.3390/cancers15235505